|
|
|
4527 ROHTO PHARMACEUTICAL CO.,LTD.
|
|
| 02/12/2026 15:30 |
Financial Results Briefing for Q3 of FY2026 (April-December) |
| 02/12/2026 15:30 |
Notice of Revision of Earnings Forecast and Revision of Dividend Forecast (Dividend Increase) |
| 02/12/2026 15:30 |
Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2026 (Nine Months Ended December 31, 2025) |
| 01/07/2026 15:30 |
Acquisition of shares (subsidiarization) of a Thailand-based wellness-related company, Thann Oryza Co., Ltd. |
| 11/13/2025 15:30 |
Consolidated Financial Results for the Six Months Ended September 30, 2025 |
| 11/13/2025 15:30 |
ROHTO Pharmaceutical Acquires OBAGI-Related Trademarks in Japan |
| 11/13/2025 15:30 |
Financial Results Briefing for 1stHalf of FY2026(April -September) |
| 11/13/2025 15:30 |
Notice of Revision of Earnings Forecast and Revision of Dividend Forecast (Dividend Increase) |
| 08/06/2025 15:30 |
Notice of Revision of Earnings Forecast |
| 08/06/2025 15:30 |
Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2026 |
| 06/30/2025 18:00 |
Corporate Governance Report |
| 06/03/2025 08:00 |
NOTICE OF CONVOCATION THE 89TH ORDINARY GENERAL MEETING OF SHAREHOLDERS |
| 05/19/2025 17:30 |
Notice of Dividend of Surplus |
| 05/13/2025 15:30 |
ROHTO Pharmaceutical Co., Ltd. Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 Reference |
| 05/13/2025 15:30 |
Financial Results Briefing for the Fiscal Year Ending March 31, 2025 |
| 05/13/2025 15:30 |
Medium- to Long- Term Growth Strategy 2025-2035 |
| 05/13/2025 15:30 |
Rohto Group Medium- to Long-Term Growth Strategy 2025-2035 |
| 05/13/2025 15:30 |
Consolidated Financial Results for the Year Ended March 31, 2025 |
| 05/09/2025 12:30 |
Notice on Changes of President and Chief Operating Officer and Other Officers |
| 04/25/2025 15:00 |
Announcement of the Initiation of Domestic Phase II Clinical Trial for Heart Failure Treatment "ADR-002K" |
| 04/21/2025 16:35 |
[Delayed]Announcement of Initiation of Phase II Clinical Trial in Japan for Ophthalmic Agent "ROH-001" |
|